As federal officials move to reclassify cannabis from a Schedule I to a Schedule III drug, University of Michigan experts say the shift could open the door to more rigorous research on a substance millions of Americans already use. The article examines why the policy change matters and why scientific evidence has struggled to keep pace with public perception.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.